Format

Send to

Choose Destination
Per Med. 2014 May;11(3):263-272. doi: 10.2217/pme.14.7.

Toxicogenetics of lopinavir/ritonavir in HIV-infected European patients.

Author information

1
Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain.
2
Instituto de Farmacia, Facultad de Ciencias, Universidad Austral de Chile, Valdivia, Chile.
3
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), University of Santiago de Compostela, Spain.
4
Fundación Pública Galega de Medicina Xenómica - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) - SERGAS (Servicio Galega de Saude), Santiago de Compostela, Spain.
5
Technological University of Pereira - Colciencias, Pereira, Colombia.
6
Infectious Disease Service, University Hospital of Salamanca, Salamanca, Spain.
7
Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
8
Tormes Team, University Hospital of Salamanca, Salamanca, Spain.

Abstract

AIMS:

We present a genetic association study in 106 European HIV-infected individuals aimed at identifying and confirming polymorphisms that have a significant influence on toxicity derived from treatment with lopinavir/ritonavir (LPV/r).

PATIENTS & METHODS:

Genotyping was performed by matrix-assisted laser desorption/ionization-time of flight and KASPar® (KBiosciences, Hoddesdon, UK); LPV/r plasma concentrations were quantified using HPLC with an UV detection system and the pharmacokinetic parameters were estimated using Bayesian algorithms. Genetic association analysis was performed with PASW Statistics 18 (SPSS Inc., IL, USA) and R for Windows (Microsoft, WA, USA).

RESULTS:

Suggestive relationships have been established between lipid plasma levels and total bilirubin and SNPs in CETP, MCP1, ABCC2, LEP and SLCO1B3 genes and between diarrhea and SNPs in IL6 gene.

CONCLUSION:

Replication analysis should confirm the novel results obtained in this study prior to its application in the clinical practice to achieve a safer LPV/r-based combined antiretroviral therapy.

KEYWORDS:

HIV; adverse effects; diarrhea; dyslipidemia; lopinavir/ritonavir; metabolic syndrome; pharmacogenetics; single nucleotide polymorphism; toxicogenetics

PMID:
29764065
DOI:
10.2217/pme.14.7

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center